| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
7,833 |
6,652 |
$8.66M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
3,430 |
2,867 |
$4.85M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
7,169 |
6,165 |
$3.68M |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
10,716 |
8,074 |
$708K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
5,340 |
1,359 |
$678K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
8,343 |
6,706 |
$579K |
| G0378 |
Hospital observation service, per hour |
336 |
316 |
$579K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
1,001 |
694 |
$505K |
| 99219 |
|
230 |
200 |
$356K |
| 99220 |
|
210 |
163 |
$339K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,006 |
900 |
$327K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
1,664 |
1,515 |
$283K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,931 |
1,730 |
$208K |
| 80061 |
Lipid panel |
3,895 |
3,546 |
$190K |
| 84443 |
Thyroid stimulating hormone (TSH) |
3,084 |
2,795 |
$188K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
2,046 |
824 |
$184K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,430 |
1,330 |
$164K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
5,390 |
4,493 |
$153K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
1,892 |
1,692 |
$142K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,808 |
3,339 |
$138K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
1,505 |
457 |
$131K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
944 |
839 |
$123K |
| 80050 |
General health panel |
965 |
876 |
$122K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
922 |
813 |
$120K |
| 80053 |
Comprehensive metabolic panel |
2,674 |
2,368 |
$116K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,184 |
1,049 |
$104K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,914 |
2,663 |
$103K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
1,486 |
497 |
$90K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,171 |
1,094 |
$82K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
371 |
281 |
$75K |
| 85027 |
|
2,967 |
2,626 |
$70K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
1,572 |
1,438 |
$68K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,044 |
985 |
$67K |
| 86780 |
|
1,326 |
1,194 |
$62K |
| 82607 |
|
1,097 |
1,006 |
$61K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
707 |
544 |
$58K |
| 86803 |
|
1,081 |
980 |
$56K |
| 80076 |
|
1,593 |
1,375 |
$48K |
| 82728 |
|
864 |
776 |
$43K |
| 59025 |
Fetal non-stress test |
166 |
86 |
$43K |
| 84439 |
|
921 |
840 |
$30K |
| 85610 |
|
2,047 |
1,278 |
$29K |
| 83550 |
|
897 |
811 |
$29K |
| 81001 |
|
2,199 |
1,943 |
$26K |
| 82565 |
|
1,272 |
1,036 |
$24K |
| 86618 |
|
266 |
178 |
$23K |
| 83735 |
|
914 |
707 |
$23K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
913 |
760 |
$23K |
| 87340 |
|
543 |
468 |
$20K |
| 71046 |
Radiologic examination, chest; 2 views |
196 |
182 |
$19K |
| 86850 |
|
1,028 |
919 |
$14K |
| 83615 |
|
612 |
470 |
$14K |
| 80051 |
|
524 |
421 |
$14K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
1,184 |
942 |
$11K |
| 86901 |
|
1,011 |
902 |
$11K |
| 86900 |
|
1,010 |
902 |
$11K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
95 |
86 |
$11K |
| 82746 |
|
195 |
183 |
$11K |
| 84460 |
|
568 |
488 |
$11K |
| 82570 |
|
555 |
457 |
$10K |
| 84702 |
|
192 |
142 |
$10K |
| 84450 |
|
546 |
459 |
$10K |
| 93017 |
|
65 |
59 |
$10K |
| 85652 |
|
971 |
818 |
$10K |
| 84520 |
|
635 |
503 |
$9K |
| 86762 |
|
173 |
148 |
$9K |
| 87088 |
|
295 |
270 |
$9K |
| 80305 |
|
248 |
188 |
$8K |
| 76642 |
|
86 |
63 |
$8K |
| 82043 |
|
395 |
349 |
$8K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
82 |
66 |
$7K |
| 95806 |
|
28 |
27 |
$6K |
| 94060 |
|
20 |
13 |
$6K |
| 84100 |
|
311 |
231 |
$6K |
| 97161 |
|
58 |
53 |
$6K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
55 |
28 |
$5K |
| 87070 |
|
165 |
127 |
$5K |
| 86140 |
|
264 |
212 |
$5K |
| 94729 |
|
65 |
54 |
$5K |
| 82947 |
|
311 |
246 |
$4K |
| 81025 |
|
169 |
125 |
$4K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
90 |
90 |
$4K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
20 |
18 |
$3K |
| 87186 |
|
78 |
67 |
$3K |
| 81002 |
|
252 |
159 |
$2K |
| 81003 |
|
244 |
193 |
$2K |
| 71250 |
|
12 |
12 |
$2K |
| 83655 |
|
57 |
38 |
$2K |
| 93018 |
|
62 |
58 |
$2K |
| 82248 |
|
92 |
65 |
$2K |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
15 |
14 |
$2K |
| 85730 |
|
75 |
57 |
$2K |
| 84481 |
|
20 |
13 |
$1K |
| 87077 |
|
34 |
29 |
$1K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
13 |
13 |
$720.00 |
| 85046 |
|
31 |
27 |
$683.01 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
16 |
14 |
$666.08 |
| 86706 |
|
18 |
13 |
$662.94 |
| 82550 |
|
27 |
24 |
$633.99 |
| 86431 |
|
29 |
27 |
$611.13 |
| 82950 |
|
33 |
32 |
$537.24 |
| 84550 |
|
12 |
12 |
$219.96 |
| 90686 |
|
522 |
374 |
$5.23 |
| 90674 |
|
124 |
86 |
$1.24 |